JP2006316040A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006316040A5 JP2006316040A5 JP2005310518A JP2005310518A JP2006316040A5 JP 2006316040 A5 JP2006316040 A5 JP 2006316040A5 JP 2005310518 A JP2005310518 A JP 2005310518A JP 2005310518 A JP2005310518 A JP 2005310518A JP 2006316040 A5 JP2006316040 A5 JP 2006316040A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- subject
- chemotherapeutic agent
- her2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 123
- 239000002246 antineoplastic agent Substances 0.000 claims 31
- 229940127089 cytotoxic agent Drugs 0.000 claims 31
- 229940022353 herceptin Drugs 0.000 claims 26
- 229960000575 trastuzumab Drugs 0.000 claims 24
- 238000000034 method Methods 0.000 claims 21
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 18
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 18
- 230000000683 nonmetastatic effect Effects 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 230000004083 survival effect Effects 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 14
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 12
- 229930012538 Paclitaxel Natural products 0.000 claims 10
- 229960001592 paclitaxel Drugs 0.000 claims 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 10
- 206010061819 Disease recurrence Diseases 0.000 claims 9
- 238000002512 chemotherapy Methods 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 238000011470 radical surgery Methods 0.000 claims 7
- 238000009098 adjuvant therapy Methods 0.000 claims 6
- 210000001165 lymph node Anatomy 0.000 claims 5
- 238000001356 surgical procedure Methods 0.000 claims 5
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 4
- 229960004397 cyclophosphamide Drugs 0.000 claims 4
- 229960003668 docetaxel Drugs 0.000 claims 4
- 102000015694 estrogen receptors Human genes 0.000 claims 4
- 108010038795 estrogen receptors Proteins 0.000 claims 4
- 102000003998 progesterone receptors Human genes 0.000 claims 4
- 108090000468 progesterone receptors Proteins 0.000 claims 4
- 238000011498 curative surgery Methods 0.000 claims 3
- 230000000977 initiatory effect Effects 0.000 claims 3
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 2
- 241000863480 Vinca Species 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 229940046836 anti-estrogen Drugs 0.000 claims 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims 2
- 238000009175 antibody therapy Methods 0.000 claims 2
- 239000003886 aromatase inhibitor Substances 0.000 claims 2
- 229960004117 capecitabine Drugs 0.000 claims 2
- 238000004590 computer program Methods 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 239000000328 estrogen antagonist Substances 0.000 claims 2
- 229960005420 etoposide Drugs 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 claims 2
- 150000003058 platinum compounds Chemical class 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 229960001196 thiotepa Drugs 0.000 claims 2
- 230000035899 viability Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000001755 vocal effect Effects 0.000 claims 1
Images
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68112505P | 2005-05-13 | 2005-05-13 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013092728A Division JP6133668B2 (ja) | 2005-05-13 | 2013-04-25 | Herceptin(登録商標)補助療法 |
| JP2013109685A Division JP2013163694A (ja) | 2005-05-13 | 2013-05-24 | Herceptin(登録商標)補助療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006316040A JP2006316040A (ja) | 2006-11-24 |
| JP2006316040A5 true JP2006316040A5 (cg-RX-API-DMAC10.html) | 2008-12-04 |
Family
ID=37450489
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005310518A Pending JP2006316040A (ja) | 2005-05-13 | 2005-10-25 | Herceptin(登録商標)補助療法 |
| JP2013092728A Expired - Lifetime JP6133668B2 (ja) | 2005-05-13 | 2013-04-25 | Herceptin(登録商標)補助療法 |
| JP2013109685A Pending JP2013163694A (ja) | 2005-05-13 | 2013-05-24 | Herceptin(登録商標)補助療法 |
| JP2015140158A Withdrawn JP2015187168A (ja) | 2005-05-13 | 2015-07-14 | Herceptin(登録商標)補助療法 |
| JP2017088352A Pending JP2017132806A (ja) | 2005-05-13 | 2017-04-27 | Herceptin(登録商標)補助療法 |
| JP2017088351A Withdrawn JP2017132805A (ja) | 2005-05-13 | 2017-04-27 | Herceptin(登録商標)補助療法 |
| JP2018200936A Pending JP2019011374A (ja) | 2005-05-13 | 2018-10-25 | Herceptin(登録商標)補助療法 |
| JP2020041610A Withdrawn JP2020094061A (ja) | 2005-05-13 | 2020-03-11 | Herceptin(登録商標)補助療法 |
| JP2022075920A Pending JP2022093642A (ja) | 2005-05-13 | 2022-05-02 | Herceptin(登録商標)補助療法 |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013092728A Expired - Lifetime JP6133668B2 (ja) | 2005-05-13 | 2013-04-25 | Herceptin(登録商標)補助療法 |
| JP2013109685A Pending JP2013163694A (ja) | 2005-05-13 | 2013-05-24 | Herceptin(登録商標)補助療法 |
| JP2015140158A Withdrawn JP2015187168A (ja) | 2005-05-13 | 2015-07-14 | Herceptin(登録商標)補助療法 |
| JP2017088352A Pending JP2017132806A (ja) | 2005-05-13 | 2017-04-27 | Herceptin(登録商標)補助療法 |
| JP2017088351A Withdrawn JP2017132805A (ja) | 2005-05-13 | 2017-04-27 | Herceptin(登録商標)補助療法 |
| JP2018200936A Pending JP2019011374A (ja) | 2005-05-13 | 2018-10-25 | Herceptin(登録商標)補助療法 |
| JP2020041610A Withdrawn JP2020094061A (ja) | 2005-05-13 | 2020-03-11 | Herceptin(登録商標)補助療法 |
| JP2022075920A Pending JP2022093642A (ja) | 2005-05-13 | 2022-05-02 | Herceptin(登録商標)補助療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US8591897B2 (cg-RX-API-DMAC10.html) |
| JP (9) | JP2006316040A (cg-RX-API-DMAC10.html) |
| AR (4) | AR054254A1 (cg-RX-API-DMAC10.html) |
| BR (1) | BRPI0601736A (cg-RX-API-DMAC10.html) |
| CA (2) | CA2540547C (cg-RX-API-DMAC10.html) |
| MX (2) | MX383973B (cg-RX-API-DMAC10.html) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| WO2001089566A1 (en) | 2000-05-19 | 2001-11-29 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| UA90480C2 (uk) | 2004-07-22 | 2010-05-11 | Джэнэнтэк, Инк. | Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA2587519A1 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| EP3698807A1 (en) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
| RS53128B (sr) | 2005-02-23 | 2014-06-30 | Genentech Inc. | Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| RU2451031C2 (ru) | 2006-01-20 | 2012-05-20 | Дженентек, Инк. | Антитела к эфрину в2 и способы их применения |
| EP1913958B1 (en) * | 2006-08-03 | 2009-12-23 | Sanofi-Aventis | Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab |
| EP2109462A1 (en) * | 2007-01-29 | 2009-10-21 | Nerviano Medical Sciences S.r.l. | Antitumor combination comprising a morpholinyl anthracycline and an antibody |
| MX2009008981A (es) | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
| KR100972618B1 (ko) | 2007-10-19 | 2010-07-27 | 국립암센터 | 허셉틴을 이용한 유방암 진단 키트, 조성물 및 이들을이용하여 허셉틴 민감성 her2 과발현 세포를 검출하는방법 |
| WO2009086197A1 (en) * | 2007-12-20 | 2009-07-09 | Monogram Biosciences, Inc. | Her-2 diagnostic methods |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
| US9879267B2 (en) * | 2008-03-14 | 2018-01-30 | Genentech, Inc. | Genetic variations associated with drug resistance |
| NZ587706A (en) * | 2008-03-18 | 2012-12-21 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| WO2009131673A1 (en) * | 2008-04-25 | 2009-10-29 | Ludwig Institute For Cancer Research Ltd. | Targeted treatment for subjects with estrogen receptor negative and progesterone receptor negative breast cancers |
| ES2342646B1 (es) * | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| DK2322221T3 (da) | 2008-08-05 | 2014-09-01 | Toray Industries | Farmaceutisk sammensætning til behandling og forebyggelse af cancer |
| MX337991B (es) | 2008-08-05 | 2016-03-30 | Toray Industries | Metodo para detectar cancer. |
| JP2012507299A (ja) | 2008-10-31 | 2012-03-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Light標的分子およびその使用 |
| EP2438442B1 (en) | 2008-12-01 | 2017-08-09 | Laboratory Corporation of America Holdings | Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95 |
| AU2009324464B2 (en) * | 2008-12-11 | 2016-05-05 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20100233732A1 (en) * | 2009-01-15 | 2010-09-16 | Laboratory Corporation Of America Holdings | Methods of Determining Patient Response By Measurement of HER-2 Expression |
| BRPI1007321A2 (en) | 2009-01-15 | 2018-07-10 | Laboratory Corporation Of America Holdings | methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody. |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| US20120128587A1 (en) * | 2009-07-31 | 2012-05-24 | Endocyte, Inc. | Folate-targeted diagnostics and treatment |
| BR112012018951C8 (pt) | 2010-02-04 | 2020-06-23 | Toray Industries | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica |
| HUE040012T2 (hu) | 2010-02-04 | 2019-02-28 | Toray Industries | Gyógyászati ágens rák kezelésére és/vagy megelõzésére |
| KR101871704B1 (ko) | 2010-02-04 | 2018-06-27 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| JP5845899B2 (ja) | 2010-02-04 | 2016-01-20 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
| AU2011211699B2 (en) | 2010-02-04 | 2015-01-22 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| KR101842893B1 (ko) | 2010-02-04 | 2018-03-28 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| WO2012078771A1 (en) * | 2010-12-09 | 2012-06-14 | Genentech, Inc. | Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1 |
| MX348579B (es) | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| KR101968499B1 (ko) | 2011-08-04 | 2019-04-12 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| CN103764825B (zh) | 2011-08-04 | 2015-09-02 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| PT2740796T (pt) | 2011-08-04 | 2017-07-26 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
| ES2672695T3 (es) | 2011-08-04 | 2018-06-15 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer |
| BR112014002619A2 (pt) | 2011-08-04 | 2018-10-09 | Toray Industries, Inc | composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica |
| ES2629061T3 (es) | 2011-08-04 | 2017-08-07 | Toray Industries, Inc. | Método para la detección de cáncer pancreático |
| HUE044352T2 (hu) * | 2011-10-14 | 2019-10-28 | Hoffmann La Roche | Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére |
| IN2014KN01714A (cg-RX-API-DMAC10.html) | 2012-02-21 | 2015-10-23 | Toray Industries | |
| ES2739380T3 (es) | 2012-02-21 | 2020-01-30 | Toray Industries | Composición farmacéutica para el tratamiento del cáncer |
| MX357505B (es) | 2012-02-21 | 2018-07-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| AU2013223143B2 (en) | 2012-02-21 | 2017-12-21 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| US9428581B2 (en) | 2012-03-30 | 2016-08-30 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of gallbladder cancer |
| PT2832365T (pt) | 2012-03-30 | 2018-01-24 | Toray Industries | Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático |
| CA2879185C (en) | 2012-07-19 | 2021-08-24 | Toray Industries, Inc. | Method for detecting cancer |
| WO2014014082A1 (ja) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | 癌の検出方法 |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| US20160067182A1 (en) * | 2013-04-09 | 2016-03-10 | Merrimack Pharmaceuticals, Inc. | Methods and compositions for improving outcomes of liposomal chemotherapy |
| MY173295A (en) | 2013-04-16 | 2020-01-14 | Genentech Inc | Pertuzumab variants and evaluation thereof |
| CA2918989C (en) | 2013-08-09 | 2021-11-02 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| SG11201603960XA (en) * | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| BR112016024789A2 (pt) | 2014-04-25 | 2017-10-24 | Genentech Inc | métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe |
| US9808528B2 (en) | 2014-06-18 | 2017-11-07 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
| TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗her2表位之單株抗體及其使用之方法 |
| JP6822980B2 (ja) | 2015-05-30 | 2021-01-27 | ジェネンテック, インコーポレイテッド | Her2陽性転移性乳癌の治療方法 |
| HUE044139T2 (hu) * | 2015-07-07 | 2019-09-30 | Hoffmann La Roche | Kombinált terápia egy HER2-ellenes antitest-gyógyszer konjugátummal és bcl-2 inhibitorral |
| US11554138B2 (en) | 2015-07-16 | 2023-01-17 | The University Of Hong Kong | Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| CA3032810A1 (en) * | 2016-08-02 | 2018-02-08 | Curirx Inc. | Methods for the preparation of liposomes |
| MX394860B (es) | 2016-09-27 | 2025-03-24 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
| WO2018066626A1 (ja) * | 2016-10-07 | 2018-04-12 | 第一三共株式会社 | 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療 |
| JP6914336B2 (ja) | 2016-12-28 | 2021-08-04 | ジェネンテック, インコーポレイテッド | 進行したher2発現がんの治療 |
| DK3570884T3 (da) | 2017-01-17 | 2020-11-30 | Genentech Inc | Subkutane HER2-antistofformuleringer |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| HUE064898T2 (hu) | 2017-03-02 | 2024-04-28 | Genentech Inc | HER2-pozitív emlõrák adjuváns kezelése |
| WO2018200505A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
| CN111278894A (zh) | 2017-07-06 | 2020-06-12 | 学校法人京都药科大学 | 肾脏靶向药物递送载体 |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CN109739435B (zh) * | 2018-12-03 | 2023-10-13 | 中科恒运股份有限公司 | 文件存储和更新方法及装置 |
| JP2023532122A (ja) | 2020-06-29 | 2023-07-26 | ジェネンテック, インコーポレイテッド | ペルツズマブにトラスツズマブを加えた固定用量配合剤 |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Preparations containing an antibody against HER2/NEU and their use |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| US20240238440A1 (en) | 2021-04-29 | 2024-07-18 | Hyslink Therapeutics | Preparation method for and application of antibody conjugated drug |
| WO2022262789A1 (zh) | 2021-06-17 | 2022-12-22 | 明慧医药(杭州)有限公司 | 一种抗肿瘤化合物及其应用 |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| CA3248133A1 (en) | 2022-01-24 | 2023-07-27 | Novimmune Sa | COMPOSITION AND METHODS FOR THE SELECTIVE ACTIVATION OF CYTOKINE SIGNALING PATHWAYS |
| WO2023174925A1 (en) | 2022-03-14 | 2023-09-21 | Novimmune Sa | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
| EP4710939A1 (en) * | 2023-05-09 | 2026-03-18 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Combined therapy drug comprising anti-her2 bispecific antibody and use thereof |
| JP2026526724A (ja) | 2023-07-14 | 2026-08-10 | ガーダント ヘルス, インコーポレイテッド | リキッドバイオプシーからのdnaメチル化を使用した乳房腫瘍の分類 |
| WO2025043547A1 (zh) | 2023-08-30 | 2025-03-06 | 杭州高田生物医药有限公司 | T细胞导向免疫脂质体及其用途 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935341A (en) | 1986-06-04 | 1990-06-19 | Whitehead Institute For Biomedical Research | Detection of point mutations in neu genes |
| US7838216B1 (en) | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| EP0474727B1 (en) | 1989-05-19 | 1997-07-23 | Genentech, Inc. | Her2 extracellular domain |
| US5705157A (en) | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
| DE69033842T2 (de) | 1989-08-04 | 2002-06-20 | Schering Ag | Äusserliche domäne von c-erbb-2:gp75 |
| US6884418B1 (en) | 1989-08-04 | 2005-04-26 | Berlex Laboratories, Inc. | Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5939531A (en) | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
| WO1993003741A1 (en) | 1991-08-22 | 1993-03-04 | Becton, Dickinson & Company | Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US5288477A (en) | 1991-09-27 | 1994-02-22 | Becton, Dickinson And Company | Method for prognosticating response to cancer therapy |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| WO1994009022A1 (en) | 1992-10-09 | 1994-04-28 | Oncor, Inc. | Methods for the detection of chromosome structural abnormalities by in situ hybridization to fixed tissue |
| US6733752B1 (en) | 1994-03-30 | 2004-05-11 | The Trustees Of The University Of Pennsylvania | Prevention of tumors with monoclonal antibodies against neu |
| US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
| US20030108545A1 (en) | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US5846749A (en) | 1994-10-12 | 1998-12-08 | The Regents Of The University Of California | Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5783404A (en) | 1995-04-13 | 1998-07-21 | Amgen Inc. | Methods and compositions for determining HER-2/neu expression using monoclonal antibodies |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| WO1997000271A1 (en) | 1995-06-14 | 1997-01-03 | The Regents Of The University Of California | Novel high affinity human antibodies to tumor antigens |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US5925519A (en) | 1996-06-03 | 1999-07-20 | The Regents Of The University Of California | Genetic alterations associated with prostate cancer |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| ES2293661T3 (es) | 1996-11-27 | 2008-03-16 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteinas a. |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| US20020076695A1 (en) | 1997-04-04 | 2002-06-20 | Jeffrey S. Ross | Methods for treating prostate cancer |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US6358682B1 (en) | 1998-01-26 | 2002-03-19 | Ventana Medical Systems, Inc. | Method and kit for the prognostication of breast cancer |
| US20020192211A1 (en) | 1998-03-17 | 2002-12-19 | Hudziak Robert M. | Method of treating tumor cells by inhibiting growth factor receptor function |
| PT1064027E (pt) | 1998-03-27 | 2008-09-29 | Genentech Inc | Sinergismo de ligando de apo-2 e anticorpo anti-her-2 |
| ATE370961T1 (de) | 1998-05-06 | 2007-09-15 | Genentech Inc | Reinigung von antikörpern durch ionenaustauschchromatographie |
| SE512710C2 (sv) | 1998-07-08 | 2000-05-02 | Ericsson Telefon Ab L M | Kapsel för högeffekttransistorchip för höga frekvenser innefattande en elektriskt och termiskt ledande fläns |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| CA2357525A1 (en) | 1999-01-27 | 2000-08-03 | Cornell Research Foundation, Inc. | Treating cancers associated with overexpression of her-2/neu |
| US6333348B1 (en) | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
| SI1187632T1 (sl) * | 1999-05-14 | 2009-04-30 | Genentech Inc | Zdravljenje z anti-ErbB2 protitelesi |
| JP3485252B2 (ja) | 1999-06-16 | 2004-01-13 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 情報処理方法、情報端末支援サーバ、コラボレーション・システム、情報処理プログラムを格納する記憶媒体 |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| EP2977063A1 (en) * | 1999-06-25 | 2016-01-27 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP2110138A1 (en) * | 1999-08-27 | 2009-10-21 | Genentech, Inc. | Dosages for treatment of anti-erbB2 antibodies |
| US7303749B1 (en) | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| JP4776843B2 (ja) | 1999-10-01 | 2011-09-21 | イムノゲン インコーポレーティッド | 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法 |
| CA2397349A1 (en) | 2000-02-29 | 2001-09-07 | Ivan David Horak | Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US6767541B2 (en) | 2000-03-20 | 2004-07-27 | The Regents Of The University Of California | HER-2/neu overexpression abrogates growth inhibitory pathways |
| GB0008368D0 (en) | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
| CA2404919A1 (en) | 2000-04-06 | 2002-10-01 | Kyowa Hakko Kogyo Co. Ltd. | Diagnostic and therapeutic agents for rheumatoid arthritis |
| US7306801B2 (en) | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
| WO2001089566A1 (en) | 2000-05-19 | 2001-11-29 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| TWI317285B (en) | 2000-07-28 | 2009-11-21 | Dainippon Sumitomo Pharma Co | New use and kit for remedies for cancer |
| US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
| NZ546251A (en) | 2000-12-01 | 2008-01-31 | Response Genetics Inc | Method of determining epidermal growth factor receptor gene expression in a parafin embedded tiasue sample and correlation of levels thereof with survival rates |
| US6602670B2 (en) | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
| US6582919B2 (en) | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
| US7005278B2 (en) | 2001-03-02 | 2006-02-28 | Danenberg Kathleen D | Method of determining dihydropyrimidine dehydrogenase gene expression |
| US20020142328A1 (en) | 2000-12-01 | 2002-10-03 | Danenberg Kathleen D. | Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors |
| AU2002239486A1 (en) | 2000-12-08 | 2002-06-18 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
| US20040138160A1 (en) | 2001-04-27 | 2004-07-15 | Kenichiro Naito | Preventive/therapeutic method for cancer |
| US20030068318A1 (en) | 2001-09-28 | 2003-04-10 | O'brien Timothy | Treatment of uterine serous papillary cancer |
| US20030175845A1 (en) | 2002-03-13 | 2003-09-18 | Kalbag Suresh M. | Use of sulfitolysis in high performance peptide mapping |
| US20030190689A1 (en) | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
| JP2005522514A (ja) | 2002-04-10 | 2005-07-28 | ジェネンテック・インコーポレーテッド | 抗her2抗体改変体 |
| ITTO20020340A1 (it) | 2002-04-19 | 2003-10-20 | Biother Di Contardi Gabriella | Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato. |
| US20030202973A1 (en) | 2002-04-29 | 2003-10-30 | Dr. George Pieczenik | Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists |
| NZ535992A (en) | 2002-05-17 | 2008-11-28 | Aventis Pharma Sa | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer |
| HUP0600340A3 (en) | 2002-07-15 | 2011-06-28 | Genentech Inc | Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies |
| US20040013297A1 (en) | 2002-07-18 | 2004-01-22 | Roger Lo | Method for performing color gamut compression |
| PT1543038T (pt) | 2002-09-11 | 2017-07-07 | Genentech Inc | Purificação de proteína |
| EP1572972A4 (en) | 2002-11-21 | 2007-11-21 | Genentech Inc | THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES |
| US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| KR20060080535A (ko) * | 2003-05-14 | 2006-07-10 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
| NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
-
2005
- 2005-10-25 JP JP2005310518A patent/JP2006316040A/ja active Pending
-
2006
- 2006-03-21 CA CA2540547A patent/CA2540547C/en not_active Expired - Lifetime
- 2006-03-21 CA CA2790058A patent/CA2790058C/en not_active Expired - Lifetime
- 2006-04-06 US US11/400,638 patent/US8591897B2/en active Active
- 2006-04-21 MX MX2018000183A patent/MX383973B/es unknown
- 2006-04-21 MX MX2013009514A patent/MX344809B/es unknown
- 2006-04-21 AR AR20060101586A patent/AR054254A1/es unknown
- 2006-04-25 BR BRPI0601736-3A patent/BRPI0601736A/pt not_active Application Discontinuation
-
2011
- 2011-08-08 US US13/205,523 patent/US8597654B2/en not_active Expired - Lifetime
-
2012
- 2012-10-03 AR ARP120103682A patent/AR088110A2/es unknown
-
2013
- 2013-04-25 JP JP2013092728A patent/JP6133668B2/ja not_active Expired - Lifetime
- 2013-05-24 JP JP2013109685A patent/JP2013163694A/ja active Pending
- 2013-10-25 US US14/063,885 patent/US20140086940A1/en not_active Abandoned
-
2015
- 2015-07-14 JP JP2015140158A patent/JP2015187168A/ja not_active Withdrawn
-
2017
- 2017-02-09 US US15/428,807 patent/US20180236093A1/en not_active Abandoned
- 2017-04-27 JP JP2017088352A patent/JP2017132806A/ja active Pending
- 2017-04-27 JP JP2017088351A patent/JP2017132805A/ja not_active Withdrawn
- 2017-05-15 AR ARP170101287A patent/AR109246A2/es unknown
- 2017-05-17 AR ARP170101322A patent/AR108615A2/es unknown
-
2018
- 2018-10-25 JP JP2018200936A patent/JP2019011374A/ja active Pending
-
2020
- 2020-01-30 US US16/777,345 patent/US20200155701A1/en not_active Abandoned
- 2020-03-11 JP JP2020041610A patent/JP2020094061A/ja not_active Withdrawn
-
2022
- 2022-05-02 JP JP2022075920A patent/JP2022093642A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jain et al. | Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy | |
| Nilsson et al. | Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study | |
| Freedman* | Follicular lymphoma: 2012 update on diagnosis and management | |
| Rechoum et al. | AR collaborates with ERα in aromatase inhibitor-resistant breast cancer | |
| Piccart et al. | Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer | |
| Lippman et al. | Cancer prevention: from 1727 to milestones of the past 100 years | |
| Kiesewetter et al. | A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) | |
| Siebels et al. | A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients | |
| Komrokji et al. | Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes | |
| Mamounas | NSABP breast cancer clinical trials: recent results and future directions | |
| Bartsch et al. | Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study | |
| Ryan et al. | Randomized phase 3 trial of abiraterone acetate in men with metastatic castration-resistant prostate cancer and no prior chemotherapy | |
| Liebner et al. | Thyroid cancer: pathogenesis and targeted therapy | |
| Huszno et al. | Cardiac side effects of trastuzumab in breast cancer patients–single centere experiences | |
| Eigl et al. | A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209 | |
| Sharma et al. | PARP pioneers: Using BRCA1/2 mutation-targeted inhibition to revolutionize breast cancer treatment | |
| Witzig et al. | A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B‐cell non‐Hodgkin lymphoma: ECOG 3402 | |
| Futamura et al. | Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial | |
| Bae et al. | Palliative radiotherapy in patients with a symptomatic pelvic mass of metastatic colorectal cancer | |
| Yamaguchi et al. | Mitigative efficacy of the clinical dosage administration of granulocyte colony-stimulating factor and romiplostim in mice with severe acute radiation syndrome | |
| Bramwell et al. | A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA. 12) | |
| Lin et al. | Phase II study of CT-2103 as first-or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions | |
| Delbaldo et al. | A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil–epirubicine–cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000) | |
| Merrell et al. | 1p/19q chromosome deletions in metastatic oligodendroglioma | |
| Salim et al. | Metformin potentiates the chemotherapeutic effects of doxorubicin on 2‐amino‐1‐methyl‐6‐phenylimidazo [4, 5b] pyridine‐induced mammary carcinoma in rats |